OcuDyne is developing a series of minimally invasive therapeutic devices and procedures designed to treat AMD by improving blood flow to the eye. The first patient population targeted for treatment are those experiencing profound vision loss due to dry AMD.

Clinical Trials

OcuDyne is currently conducting clinical trials in Argentina and Australia.

More information about these studies and contact information can be found at: